Helsinki, 17 March 2026 – Tenboron Oy, a Finnish biotech company developing novel boron carriers, has received a positive funding decision from the European Union
Dr. Ataman succeeds Dr. Seppo Pakkala in this position. Dr. Pakkala continues to serve on the Board of Directors and advises Tenboron on medical topics.
The first patients have received BNCT treatment at the HUS Comprehensive Cancer Center in Helsinki, Finland: https://www.hus.fi/en/newsroom/bnct-treatments-cancer-patients-have-started-part-clinical-trial
Dr. Ataman is specialized in clinical radiation related research with technical and in depth understanding of radiation biology and physics as well as clinical endpoints
The first patient has enrolled in the Phase I clinical trial and was dosed on Sunday, April 14. No acute safety issues were reported.
Tenboron’s background and BNCT technology are presented in this post: https://www.suomenbioteollisuus.fi/post/finnish-company-tenboron-develops-groundbreaking-cancer-treatment
